Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
27,610,121
-
Share change
-
-1,942,608
-
Total reported value
-
$489,765,707
-
Put/Call ratio
-
667%
-
Price per share
-
$18.18
-
Number of holders
-
68
-
Value change
-
-$39,910,866
-
Number of buys
-
35
-
Number of sells
-
30
Institutional Holders of Silence Therapeutics plc - ADS (SLN) as of Q3 2024
As of 30 Sep 2024,
Silence Therapeutics plc - ADS (SLN) was held by
68 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,610,121 shares.
The largest 10 holders included
TCG Crossover Management, LLC, Siren, L.L.C., Lombard Odier Asset Management (USA) Corp, Redmile Group, LLC, Frazier Life Sciences Management, L.P., MILLENNIUM MANAGEMENT LLC, Vivo Capital, LLC, JANUS HENDERSON GROUP PLC, Deep Track Capital, LP, and Polar Capital Holdings Plc.
This page lists
68
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.